Ziad F. Gellad, MD, MPH
Department / Division
Medicine /
Medicine - Gastroenterology
Address
508 Fulton Street (111E)
Durham, NC 27705
Office Telephone
919-286-0411, ext. 6945
Fax Telephone
919-416-5815
- MD, Johns Hopkins University School of Medicine (Maryland), 2003
- Internal Medicine, Duke University Medical Center, 2003-2006
- Gastroenterology, Duke University Medical Center, 2006-2009
- MPH, Johns Hopkins University School of Public Health (Maryland), 2002
Clinical Interests
General gastroenterology; diagnostic and therapeutic endoscopy; colon cancer screening and surveillance; health-services research, specifically quality, efficiency, and cost-effectiveness of medical care in gastroenterology
Research Interests
I am a gastroenterologist and health services researcher with an interest in optimizing health care value. My research is focused on three areas that address both cost and quality in gastroenterology:
1) Cost-Effectiveness of hepatitis C therapy: In collaboration with colleagues in hepatology, we are developing decision models for hepatitis C therapy that enable evaluation of new therapies and novel treatment paradigms.
2) Efficiency of gastrointestinal endoscopy: In collaboration with colleagues in industrial engineering, we are building discrete event simulation models of ambulatory and hospital based endoscopy centers. These models are used to optimize operational efficiency as well as measure quality in endoscopy.
3) Quality of colorectal cancer screening: We are evaluating the processes and outcomes of colorectal cancer screening using both fecal occult blood testing and colonoscopy. We are also designing intervention studies to improve the processes of care.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Pentax Corp.
- Salix Pharmaceuticals, Ltd.
Representative Publications
Gellad ZF, Stechuchak KM, Fisher DA, Olsen MK, McDuffie JR, Ostbye T, Yancy WS Jr. Longitudinal Adherence to Fecal Occult Blood Testing Impacts Colorectal Cancer Screening Quality. Am J Gastroenterol. 2011 Feb 8.
(2011)
Abstract
Gellad ZF, Provenzale D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology. 2010 Jun;138(6):2177-90.
(2010)
Abstract
Gellad ZF, Weiss DG, Ahnen DJ, Lieberman DA, Jackson GL, Provenzale D. Colonoscopy Withdrawal Time and Risk of Neoplasia at 5 Years: Results From VA Cooperative Studies Program 380. Am J Gastroenterol. 2010 Mar 16.
(2010)
Abstract
Jackson GL, Melton LD, Abbott DH, Zullig LL, Ordin DL, Grambow SC, Hamilton NS, Zafar SY, Gellad ZF, Kelley MJ, Provenzale D. Quality of Nonmetastatic Colorectal Cancer Care in the Department of Veterans Affairs. J Clin Oncol. 2010 Jun 1.
(2010)
Abstract
Gellad ZF, Almirall D, Provenzale D, Fisher DA. Time from Positive Screening Fecal Occult Blood Test to Colonoscopy and Risk of Neoplasia. Dig Dis Sci. 2008 Dec 18.
(2008)
Abstract
